» Articles » PMID: 16988660

Gene Therapy: is IL2RG Oncogenic in T-cell Development?

Overview
Journal Nature
Specialty Science
Date 2006 Sep 22
PMID 16988660
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The gene IL2RG encodes the gamma-chain of the interleukin-2 receptor and is mutated in patients with X-linked severe combined immune deficiency (X-SCID). Woods et al. report the development of thymus tumours in a mouse model of X-SCID after correction by lentiviral overexpression of IL2RG and claim that these were caused by IL2RG itself. Here we find that retroviral overexpression of IL2RG in human CD34+ cells has no effect on T-cell development, whereas overexpression of the T-cell acute lymphoblastic leukaemia (T-ALL) oncogene LMO2 leads to severe abnormalities. Retroviral expression of IL2RG may therefore not be directly oncogenic--rather, the restoration of normal signalling by the interleukin-7 receptor to X-SCID precursor cells allows progression of T-cell development to stages that are permissive for the pro-leukaemic effects of ectopic LMO2.

Citing Articles

IL-2RG as a possible immunotherapeutic target in CRC predicting poor prognosis and regulated by miR-7-5p and miR-26b-5p.

Gharib E, Rejali L, Piroozkhah M, Zonoobi E, Nasrabadi P, Arabsorkhi Z J Transl Med. 2024; 22(1):439.

PMID: 38720389 PMC: 11080123. DOI: 10.1186/s12967-024-05251-2.


Advances in gene therapy for inborn errors of immunity.

Ott de Bruin L, Lankester A, Staal F Curr Opin Allergy Clin Immunol. 2023; 23(6):467-477.

PMID: 37846903 PMC: 10621649. DOI: 10.1097/ACI.0000000000000952.


The quest for the holy grail: overcoming challenges in expanding human hematopoietic stem cells for clinical use.

Bastani S, Staal F, Cante-Barrett K Stem Cell Investig. 2023; 10:15.

PMID: 37457748 PMC: 10345135. DOI: 10.21037/sci-2023-016.


Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency Disease.

Blanco E, Izotova N, Booth C, Thrasher A Front Immunol. 2020; 11:608653.

PMID: 33329605 PMC: 7729079. DOI: 10.3389/fimmu.2020.608653.


Innovative Cell-Based Therapies and Conditioning to Cure RAG Deficiency.

Villa A, Capo V, Castiello M Front Immunol. 2020; 11:607926.

PMID: 33329604 PMC: 7711106. DOI: 10.3389/fimmu.2020.607926.